Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar...
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a...
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.33 | 5.02076255191 | 26.49 | 29.07 | 25.18 | 66418 | 27.14031865 | CS |
4 | 2.98 | 11.9967793881 | 24.84 | 29.07 | 22.51 | 70056 | 25.16712898 | CS |
12 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
26 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
52 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
156 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
260 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관